Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 13/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21943164 | 1.00 | RNASEL (0.72) | RNASEL | |
| SCHEMBL23776041 | 0.97 | RNASEL (0.66) | RNASEL | |
| SCHEMBL21943266 | 0.95 | RNASEL (0.65) | RNASEL | |
| SCHEMBL27275674 | 0.95 | RNASEL (0.65) | RNASEL | |
| SCHEMBL27273300 | 0.95 | RNASEL (0.64) | RNASEL | |
| SCHEMBL27273288 | 0.95 | RNASEL (0.64) | RNASEL | |
| SCHEMBL21942787 | 0.94 | RNASEL (0.63) | RNASEL | |
| SCHEMBL23776034 | 0.94 | RNASEL (0.63) | RNASEL | |
| SCHEMBL24499599 | 0.94 | RNASEL (0.63) | RNASEL | |
| SCHEMBL18521686 | 0.94 | RNASEL (0.63) | RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | RNASEL 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.